Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study

BMC Gastroenterology

Research

Heejin Cho¹  Yun Bin Lee²  Kyu Sung Rim³  Yeonjung Ha³  Mi Na Kim³  Joo Ho Lee³  Seong Gyu Hwang³  Young Eun Chon³  Hana Park⁴ 

[1] Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, 03080, Seoul, Republic of Korea;Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, 03080, Seoul, Republic of Korea;Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea;Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea;Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea;Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea;

关键词: Liver stiffness;    Transient elastography;    Tenofovir disoproxil fumarate;    Chronic hepatitis B;   

DOI  :  10.1186/s12876-023-02846-9

 received in 2022-09-14, accepted in 2023-06-06,  发布年份 2023

来源: Springer

【 摘 要 】

Background/AimsRegression of liver fibrosis during antiviral therapy in chronic hepatitis B (CHB) patients has been demonstrated, but data on the influence of long-term treatment with tenofovir disoproxil fumarate (TDF) on liver stiffness (LS) measured by transient elastography are scarce. We aimed to investigate the changes in LS values during the 144-week TDF therapy in treatment-naïve CHB patients.MethodsThis prospective observational study was conducted from April 2015 to July 2020 at CHA Bundang Medical Center. Laboratory tests and LS measurements were performed at baseline and repeated at weeks 12, 24, 48, 96, and 144. A significant decline in LS was defined as ≥ 30% decrease in LS value at week 96 from baseline.ResultsA total of 48 treatment-naïve CHB patients initiating TDF therapy were screened, and 36 patients were included in the final analysis (median age, 46 [interquartile range, 34.5–55.8] years; 19 men [52.8%]). During TDF therapy, the median LS values decreased from 13.8 kPa at baseline to 8.7 kPa, 6.5 kPa, and 6.4 kPa at weeks 48, 96, and 144, respectively (all P < 0.001). At week 96, virological and biochemical responses were achieved in 34 (94.4%) patients and 20 (76.9%) patients, respectively. Moreover, 21 of 36 (58.3%) patients showed a significant decline in LS value. A higher baseline LS value was a single independent predictor for the reduction in LS value at week 96 from baseline (P < 0.001).ConclusionsDuring the 144-week TDF therapy, LS values declined significantly in treatment-naïve CHB patients.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 4

40517_2023_252_Article_IEq137.gif